AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares
XASE · usd
SIC 8733
FIGI BBG003CMFFC8
1.78▼ 0.05 (-2.73%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
1.83
Day's Range
1.77 – 1.82
52-Week Range
0.17 – 10.40
Volume
23.8K
Avg Volume
36.8K
Share Statistics
Shares Outstanding
Employees
5
Exchange
XASE
Listed
2012-09-10
Share count as of June 30, 2026

Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Market Cap?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Market Cap is $7.6M, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Enterprise Value?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Enterprise Value is $1.2M, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Price / Sales?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Price / Sales is 13.6×, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / Revenue?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / Revenue is 2.1×, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / EBITDA?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Revenue (TTM)?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Revenue (TTM) is $560.0K, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Net Income (TTM)?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Net Income (TTM) is -$8.8M, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA is -$8.9M, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Diluted EPS (TTM)?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's Diluted EPS (TTM) is -2.05, based on as-reported figures from SEC (XBRL) filings.
What is Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA Margin?
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares's EBITDA Margin is -1594.1%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CANFAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(as filed, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Revenues
YoY growth-39.9%
Research and development expenses
General and administrative expenses
Operating loss
% of revenue-2456.8%
Financial income, net
Basic net loss per share (in Dollars per share)
Diluted net loss per share (in Dollars per share)